BOSTON--(BUSINESS WIRE)--Dec. 5, 2018--
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused
on developing and commercializing medicines to improve the survival and
quality of life of cancer patients, today announced the grant of options
to purchase 83,978 shares of its common stock to four employees. The
awards were granted as an inducement material to the employees'
acceptance of employment with Verastem Oncology in accordance with
Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal
to $5.21 per share, the closing price of Verastem Oncology's common
stock as reported by Nasdaq on December 3, 2018 and vest at a rate of
20% on the one-year anniversary of his or her date of hire, and
thereafter, at a rate of 5% of the shares subject to the options at the
end of each successive three-month period, provided that the employee
continues to serve as an employee of or other service provider to
Verastem Oncology on each such vesting date.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical
company committed to the development and commercialization of medicines
to improve the lives of patients diagnosed with cancer. We are driven by
the strength, tenacity and courage of those battling cancer –
single-minded in our resolve to deliver new therapies that not only keep
cancer at bay, but improve the lives of patients diagnosed with cancer.
Because for us, it’s personal.
Our first FDA approved product is now available for the treatment of
patients with certain types of indolent non-Hodgkin’s lymphoma (iNHL).
Our pipeline comprises product candidates that seek to treat cancer by
modulating the local tumor microenvironment. For more information,
please visit www.verastem.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181205005650/en/
Source: Verastem, Inc.